Core Viewpoint - The article discusses a breakthrough in medical technology that allows for the safe opening and closing of the blood-brain barrier (BBB) using an ultrasound-based device, UltraBrainPad, to enhance drug delivery for treating glioblastoma patients [1][2]. Group 1: Technology and Methodology - The UltraBrainPad device utilizes ultrasound neuroregulation technology to open the BBB in glioblastoma patients, significantly increasing drug concentration in the brain by an average of 8 times compared to untreated brain tissue [1][2]. - The entire process of opening the BBB takes only 3 minutes, and the BBB can be safely closed again 6 hours after treatment, ensuring both efficacy and safety [1][2]. - The device allows for real-time observation of the brain's condition and the degree of BBB opening through a handheld ultrasound probe, enhancing the precision of the treatment [2]. Group 2: Clinical Implications - Glioblastoma accounts for approximately 30% of all malignant brain tumors, with an average survival time of around 16 months, highlighting the need for more effective treatment methods [2]. - Traditional chemical treatments for glioblastoma have been largely ineffective due to the BBB, prompting the exploration of physical methods like ultrasound to improve drug delivery [2]. - The research team aims to expand the application of ultrasound neuroregulation technology to various brain diseases in future clinical trials, potentially benefiting a wider range of patients [3].